HPV-related oropharynx cancer in the United KingdomCitation formats

  • External authors:
  • Andrew G. Schache
  • Ned G. Powell
  • Kate S. Cuschieri
  • Max Robinson
  • Sam Leary
  • Hisham Mehanna
  • Davy Rapozo
  • Anna Long
  • Heather Cubie
  • Elizabeth Junor
  • Hannah Monaghan
  • Kevin J. Harrington
  • Christopher M. Nutting
  • Ulrike Schick
  • Andy S. Lau
  • Navdeep Upile
  • Jon Sheard
  • Kath Brougham
  • Kenneth Oguejiofor
  • Steve Thomas
  • Andy R. Ness
  • Miranda Pring
  • Gareth J. Thomas
  • Emma V. King
  • Dennis J. McCance
  • Jacqueline A. James
  • Michael Moran
  • Phil Sloan
  • Richard J. Shaw
  • Mererid Evans
  • Terry M. Jones

Standard

HPV-related oropharynx cancer in the United Kingdom : An evolution in the understanding of disease etiology. / Schache, Andrew G.; Powell, Ned G.; Cuschieri, Kate S.; Robinson, Max; Leary, Sam; Mehanna, Hisham; Rapozo, Davy; Long, Anna; Cubie, Heather; Junor, Elizabeth; Monaghan, Hannah; Harrington, Kevin J.; Nutting, Christopher M.; Schick, Ulrike; Lau, Andy S.; Upile, Navdeep; Sheard, Jon; Brougham, Kath; West, Catharine M L; Oguejiofor, Kenneth; Thomas, Steve; Ness, Andy R.; Pring, Miranda; Thomas, Gareth J.; King, Emma V.; McCance, Dennis J.; James, Jacqueline A.; Moran, Michael; Sloan, Phil; Shaw, Richard J.; Evans, Mererid; Jones, Terry M.

In: Cancer Research, Vol. 76, No. 22, 15.11.2016, p. 6598-6606.

Research output: Contribution to journalArticle

Harvard

Schache, AG, Powell, NG, Cuschieri, KS, Robinson, M, Leary, S, Mehanna, H, Rapozo, D, Long, A, Cubie, H, Junor, E, Monaghan, H, Harrington, KJ, Nutting, CM, Schick, U, Lau, AS, Upile, N, Sheard, J, Brougham, K, West, CML, Oguejiofor, K, Thomas, S, Ness, AR, Pring, M, Thomas, GJ, King, EV, McCance, DJ, James, JA, Moran, M, Sloan, P, Shaw, RJ, Evans, M & Jones, TM 2016, 'HPV-related oropharynx cancer in the United Kingdom: An evolution in the understanding of disease etiology', Cancer Research, vol. 76, no. 22, pp. 6598-6606. https://doi.org/10.1158/0008-5472.CAN-16-0633

APA

Schache, A. G., Powell, N. G., Cuschieri, K. S., Robinson, M., Leary, S., Mehanna, H., ... Jones, T. M. (2016). HPV-related oropharynx cancer in the United Kingdom: An evolution in the understanding of disease etiology. Cancer Research, 76(22), 6598-6606. https://doi.org/10.1158/0008-5472.CAN-16-0633

Vancouver

Schache AG, Powell NG, Cuschieri KS, Robinson M, Leary S, Mehanna H et al. HPV-related oropharynx cancer in the United Kingdom: An evolution in the understanding of disease etiology. Cancer Research. 2016 Nov 15;76(22):6598-6606. https://doi.org/10.1158/0008-5472.CAN-16-0633

Author

Schache, Andrew G. ; Powell, Ned G. ; Cuschieri, Kate S. ; Robinson, Max ; Leary, Sam ; Mehanna, Hisham ; Rapozo, Davy ; Long, Anna ; Cubie, Heather ; Junor, Elizabeth ; Monaghan, Hannah ; Harrington, Kevin J. ; Nutting, Christopher M. ; Schick, Ulrike ; Lau, Andy S. ; Upile, Navdeep ; Sheard, Jon ; Brougham, Kath ; West, Catharine M L ; Oguejiofor, Kenneth ; Thomas, Steve ; Ness, Andy R. ; Pring, Miranda ; Thomas, Gareth J. ; King, Emma V. ; McCance, Dennis J. ; James, Jacqueline A. ; Moran, Michael ; Sloan, Phil ; Shaw, Richard J. ; Evans, Mererid ; Jones, Terry M. / HPV-related oropharynx cancer in the United Kingdom : An evolution in the understanding of disease etiology. In: Cancer Research. 2016 ; Vol. 76, No. 22. pp. 6598-6606.

Bibtex

@article{d9421ee002c64655ac2affb137ccb0c9,
title = "HPV-related oropharynx cancer in the United Kingdom: An evolution in the understanding of disease etiology",
abstract = "A rising incidence of oropharyngeal squamous cell carcinoma (OPSCC) incidence has occurred throughout the developed world, where it has been attributed to an increasing impact of human papillomavirus (HPV) on disease etiology. This report presents the findings of a multicenter cross-sectional retrospective study aimed at determining the proportion of HPV-positive and HPV-negative OPSCC within the United Kingdom. Archival tumor tissue blocks from 1,602 patients previously diagnosed with OPSCC (2002-2011) were collated from 11 centers. HPV status was determined with three validated commercial tests to provide valid data for 1,474 cases in total. Corresponding national incidence data from the same decade were obtained from UK Cancer registries. The overall proportion of HPV+ OPSCC between 2002 and 2011 was 51.8{\%} [95{\%} confidence interval (CI), 49.3-54.4], and this remained unchanged throughout the decade [unadjusted RR = 1.00 (95{\%} CI, 0.99-1.02)]. However, over the same period, the incidence of OPSCC in the broader UK population underwent a 2-fold increase [age-standardized rate 2002: 2.1 (95{\%} CI, 1.9-2.2); 2011: 4.1 (95{\%} CI, 4.0-4.3)]. Although the number of OPSCCs diagnosed within the United Kingdom from 2002 to 2011 nearly doubled, the proportion of HPV+ cases remained static at approximately 50{\%}. Our results argue that the rapidly increasing incidence of OPSCC in the United Kingdom cannot be solely attributable to the influence of HPV. The parallel increase in HPV+ and HPV- cases we documented warrants further investigation, so that appropriate future prevention strategies for both types of disease can be implemented.",
author = "Schache, {Andrew G.} and Powell, {Ned G.} and Cuschieri, {Kate S.} and Max Robinson and Sam Leary and Hisham Mehanna and Davy Rapozo and Anna Long and Heather Cubie and Elizabeth Junor and Hannah Monaghan and Harrington, {Kevin J.} and Nutting, {Christopher M.} and Ulrike Schick and Lau, {Andy S.} and Navdeep Upile and Jon Sheard and Kath Brougham and West, {Catharine M L} and Kenneth Oguejiofor and Steve Thomas and Ness, {Andy R.} and Miranda Pring and Thomas, {Gareth J.} and King, {Emma V.} and McCance, {Dennis J.} and James, {Jacqueline A.} and Michael Moran and Phil Sloan and Shaw, {Richard J.} and Mererid Evans and Jones, {Terry M.}",
year = "2016",
month = "11",
day = "15",
doi = "10.1158/0008-5472.CAN-16-0633",
language = "English",
volume = "76",
pages = "6598--6606",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research",
number = "22",

}

RIS

TY - JOUR

T1 - HPV-related oropharynx cancer in the United Kingdom

T2 - An evolution in the understanding of disease etiology

AU - Schache, Andrew G.

AU - Powell, Ned G.

AU - Cuschieri, Kate S.

AU - Robinson, Max

AU - Leary, Sam

AU - Mehanna, Hisham

AU - Rapozo, Davy

AU - Long, Anna

AU - Cubie, Heather

AU - Junor, Elizabeth

AU - Monaghan, Hannah

AU - Harrington, Kevin J.

AU - Nutting, Christopher M.

AU - Schick, Ulrike

AU - Lau, Andy S.

AU - Upile, Navdeep

AU - Sheard, Jon

AU - Brougham, Kath

AU - West, Catharine M L

AU - Oguejiofor, Kenneth

AU - Thomas, Steve

AU - Ness, Andy R.

AU - Pring, Miranda

AU - Thomas, Gareth J.

AU - King, Emma V.

AU - McCance, Dennis J.

AU - James, Jacqueline A.

AU - Moran, Michael

AU - Sloan, Phil

AU - Shaw, Richard J.

AU - Evans, Mererid

AU - Jones, Terry M.

PY - 2016/11/15

Y1 - 2016/11/15

N2 - A rising incidence of oropharyngeal squamous cell carcinoma (OPSCC) incidence has occurred throughout the developed world, where it has been attributed to an increasing impact of human papillomavirus (HPV) on disease etiology. This report presents the findings of a multicenter cross-sectional retrospective study aimed at determining the proportion of HPV-positive and HPV-negative OPSCC within the United Kingdom. Archival tumor tissue blocks from 1,602 patients previously diagnosed with OPSCC (2002-2011) were collated from 11 centers. HPV status was determined with three validated commercial tests to provide valid data for 1,474 cases in total. Corresponding national incidence data from the same decade were obtained from UK Cancer registries. The overall proportion of HPV+ OPSCC between 2002 and 2011 was 51.8% [95% confidence interval (CI), 49.3-54.4], and this remained unchanged throughout the decade [unadjusted RR = 1.00 (95% CI, 0.99-1.02)]. However, over the same period, the incidence of OPSCC in the broader UK population underwent a 2-fold increase [age-standardized rate 2002: 2.1 (95% CI, 1.9-2.2); 2011: 4.1 (95% CI, 4.0-4.3)]. Although the number of OPSCCs diagnosed within the United Kingdom from 2002 to 2011 nearly doubled, the proportion of HPV+ cases remained static at approximately 50%. Our results argue that the rapidly increasing incidence of OPSCC in the United Kingdom cannot be solely attributable to the influence of HPV. The parallel increase in HPV+ and HPV- cases we documented warrants further investigation, so that appropriate future prevention strategies for both types of disease can be implemented.

AB - A rising incidence of oropharyngeal squamous cell carcinoma (OPSCC) incidence has occurred throughout the developed world, where it has been attributed to an increasing impact of human papillomavirus (HPV) on disease etiology. This report presents the findings of a multicenter cross-sectional retrospective study aimed at determining the proportion of HPV-positive and HPV-negative OPSCC within the United Kingdom. Archival tumor tissue blocks from 1,602 patients previously diagnosed with OPSCC (2002-2011) were collated from 11 centers. HPV status was determined with three validated commercial tests to provide valid data for 1,474 cases in total. Corresponding national incidence data from the same decade were obtained from UK Cancer registries. The overall proportion of HPV+ OPSCC between 2002 and 2011 was 51.8% [95% confidence interval (CI), 49.3-54.4], and this remained unchanged throughout the decade [unadjusted RR = 1.00 (95% CI, 0.99-1.02)]. However, over the same period, the incidence of OPSCC in the broader UK population underwent a 2-fold increase [age-standardized rate 2002: 2.1 (95% CI, 1.9-2.2); 2011: 4.1 (95% CI, 4.0-4.3)]. Although the number of OPSCCs diagnosed within the United Kingdom from 2002 to 2011 nearly doubled, the proportion of HPV+ cases remained static at approximately 50%. Our results argue that the rapidly increasing incidence of OPSCC in the United Kingdom cannot be solely attributable to the influence of HPV. The parallel increase in HPV+ and HPV- cases we documented warrants further investigation, so that appropriate future prevention strategies for both types of disease can be implemented.

UR - http://www.scopus.com/inward/record.url?scp=84995537851&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-16-0633

DO - 10.1158/0008-5472.CAN-16-0633

M3 - Article

VL - 76

SP - 6598

EP - 6606

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 22

ER -